Loading...
Loading...
Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd.. Spoken Alpha tracks GLMD's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks GLMD's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 90% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for GLMD.
curl https://api.spokenalpha.com/v1/companies/GLMD| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $0.66 | $0.60 | +10.2% | -2.0% | -0.9% |
| Q4 FY2026 | $0.68 | $0.60 | +13.4% | -2.2% | -3.9% |
| Q3 FY2026 | $0.91 | $0.75 | +20.8% | -0.3% | -1.0% |
| Q2 FY2026 | $0.89 | $0.75 | +19.2% | -2.7% | -4.9% |
| Q1 FY2025 | $1.08 | $0.90 | +19.6% | -3.7% | -0.9% |
| Q4 FY2025 | $1.07 | $0.90 | +19.1% | +2.4% | +3.6% |
| Q3 FY2025 | $0.91 | $0.83 | +9.4% | -4.9% | -4.2% |
| Q2 FY2025 | $0.78 | $0.69 | +12.8% | -2.5% | -0.4% |
| Q1 FY2024 | $1.05 | $0.89 | +18.4% | -5.2% | -5.8% |
| Q4 FY2024 | $0.85 | $0.77 | +10.0% | -0.6% | -0.2% |